SUNNYVALE, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (a??Silk Road Medicala??), a company focused on reducing the risk of stroke and its devastating impact, announced today that effective as of market open on March 6, 2020, its common stock has been approved for uplisting to the Nasdaq Global Select MarketA® and will continue trading under its current ticker symbol "SILK".
About Silk Road Medical Silk Road Medical, Inc. (NASDAQ: SILK),A is a medical device company located inA Sunnyvale, California. The companya??s flagship procedure, TransCarotid Artery Revascularization (TCAR), is clinically proven to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit
www.silkroadmed.com and connect on
Twitter,
LinkedIn and
Facebook.
Investors:
Lynn Lewis or Caroline Paul
Gilmartin Group
investors@silkroadmed.comMedia:
Joni Ramirez
Merryman Communications
joni@merrymancommunications.com
